Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum circumsporozoite protein (CSP) and a moderate CD4 + T cell response. The individual contribution of these adaptive immune responses to protection from infection remains unknown. Here, we found that prophylactic administration of anti-CSP mAbs derived from an RTS,S-vaccinated recipient fully protected mice with humanized livers from i.v.-and mosquito bite-delivered P. falciparum sporozoite challenge. Titers of anti-CSP that conveyed full protection were within the range observed in human RTS,S vaccine recipients. Increasing anti-CSP titers resulted in a dose-dependent reduction of the liver parasite burden. These data indicate that RTS,S-induced antibodies are protective and provide sterilizing immunity against P. falciparum infection when reaching or exceeding a critical plasma concentration.
Results and Discussion
To evaluate the protective efficacy of anti-CSP IgG in the absence of any confounding (i.e., T cell-mediated) factors, we administered varying doses of 3 human anti-CSP mAbs (designated Mal1C, Mal2A, and Mal3B) into humanized uPA-SCID mice before exposure to P. falciparum. The human mAbs recognizing the NANP repeat region of CSP were derived from a subject vaccinated with RTS,S, as described previously (25) . uPA-SCID mice were transplanted with cryopreserved primary human hepatocytes, all from the same lot, as described previously (5) . The capacity of anti-CSP mAbs to interact with sporozoites and inhibit their motility and cell traversal has previously been examined in vitro using a gliding assay (26) and an inhibition of sporozoite invasion assay (27, 28) . The RTS,S-induced anti-CSP mAb Mal1C dose-dependently inhibited gliding motility, with complete inhibition at 1,000 EU/ml ( Figure 1 , A, C, and D). In the inhibition of sporozoite invasion assay, parasites were added to wells containing HepG2 or Huh7.5 cells. The frequency of parasites invading Huh7.5 and HepG2 cells (27) was comparable ( Figure 1 , B, E, and F). Since both assays allow for a long interaction time between antibody and sporozoite, one may wonder whether antibody concentrations that inhibit sporozoite functions in vitro are also effective in vivo, when antibodies and sporozoites can only interact during the brief passage from the mosquito bite to the liver (29) .
To examine whether human anti-CSP mAbs are capable of preventing in vivo infection with P. falciparum sporozoites, 13 humanized uPA-SCID mice were injected i.p. with PBS, and 17 mice were given varying doses of the anti-CSP mAb Mal1C: 2 mg (n = 11), 200 μg (n = 3), and 20 μg (n = 3). The following day, plasma concentrations of circulating mAbs were measured using a validated and standardized ELISA (25) . Immediately thereafter, mice were challenged either via i.v. injection of 150,000 sporozoites (7 PBS, 6 Mal1C) or by exposing each mouse to 20 P. falciparum-infected mosquitoes that were allowed to feed for 20 minutes (6 PBS, 11 Mal1C) (12). 5 days after challenge, mice were euthanized, and their livers were divided into 12 standardized sections. From each of these fragments, 25 mg was used to determine the human hepatocyte content and the P. falciparum liver load using quantitative RT-PCR (qPCR; L. Foquet, unpublished observations, and refs. 30, 31) . Regardless of infection route, all PBS-treated mice were infected with P. falciparum, and all mice pretreated with 2 mg Mal1C were protected (Table 1) . Anti-CSP plasma concentrations (geometric mean titer [GMT]) measured immediately before challenge were 3,421.5 and 3,133.4 EU/ ml in the i.v.-and mosquito bite-infected groups, respectively. After injection of 200 μg Mal1C, 2 of 3 mice were protected from infection. Antibody concentrations measured in the protected mice before infection were 139.7 and 273.1 EU/ml. The single unprotected mouse had an anti-CSP titer of 230.0 EU/ml and showed a much lower liver parasite burden than sham-treated mice (29.4 P. falciparum/10 6 human hepatocytes; Table 1 ). Liver parasite burden after treatment with 20 μg mAb in 3 mice showed minimal reduction compared with sham-treated animals. Anti-CSP mAb concentrations in these mice were 31.5, 23.7, and 13.1 EU/ml (Table 1 ). Next, we tested whether 2 additional mAbs are able to prevent P. falciparum infection when administered in a dose corresponding to serum concentrations achievable by RTS,S vaccination (18, 32) . Both Mal2A (HV3-HD3-HJ4:KV3-KJ2) and Mal3B (HV3-HD1-HJ6:KV1-KJ1) were different from Mal1C (HV3-HD3-HJ4:KV2-KJ2), as determined by sequence analysis of V H :V L pairs (33) . Groups of 3 mice were injected i.p. with 400 μg of Mal1C, Mal2A, or Mal3B and challenged the next day by infected mosquito bites ( Table 1 ). The anti-CSP plasma concentrations (GMT) measured before infection were 668.1, 723.1, and 868.4 EU/ml, respectively. As a control, 1 humanized mouse was injected with PBS and 1 with 400 μg of a control mAb directed against HBsAg, as anti-HBsAg antibodies are also induced by RTS,S. All mice treated with the anti-CSP mAbs were protected against infection, whereas both control mice were infected at day 5 after challenge.
Previous research showed that passive transfer of antibodies directed against the repeat region of P. berghei CSP is capable of arresting P. berghei sporozoite motility within the skin of mice after mosquito challenge (34) . Moreover, i.p. administration to human hepatocyte SCID mice of 2.5 mg of an anti-CSP mAb that cross-reacts with P. falciparum and P. berghei (Pf 49 1B2.2) reduced the number of infected human hepatocytes after i.v. injection of 180,000 P. falciparum sporozoites, but sterile protection was not achieved (35) . Here, we found that human anti-CSP mAbs derived from an RTS,S vaccinee were able to prevent infection of human liver uPA-SCID mice by P. falciparum when injected prior to parasite challenge, regardless of infection route (i.v. or mosquito bite). The short contact time of antibodies with parasites after nonnatural i.v. injection of sporozoites can conceal the protective effect of antibodies with lower binding affinity that may prove effective when the parasites are delivered via mosquito bite.
The anti-CSP concentrations measured immediately before parasite challenge and induced by administration of 400 μg of Mal1C, Mal2A, and Mal3B (Table 1 ) were in the same range as those previously measured in RTS,S vaccine trials using the same quantification method (25) . The lower vaccine efficacy observed in field trials may be due to a progressive decline in antibody titer during the follow-up period. Indeed, after 12 months, a 95% reduction of anti-CSP titer was observed, and antibody concentrations may drop below the level required to convey sterilizing immunity (36) . Our results demonstrated that preventing natural P. falciparum infection of humanized mice could be achieved by passive transfer of mAbs induced by RTS,S vaccination of a malaria-naive volunteer. The sterilizing immunity transferred to the humanized mice provides a proof of principle that anti-CSP antibodies induced by RTS,S are able to prevent P. falciparum infection of the liver. These findings further suggest that the protective efficacy of the RTS,S vaccine can possibly be improved by increasing the magnitude and persistence of the CSP-specific antibody response. 
